G1 Therapeutics, Inc.

2024 Q3 Form 10-Q Financial Statement

#000162828024036149 Filed on August 08, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $60.73M
YoY Change -41.74%
Cash & Equivalents $15.07M
Short-Term Investments $45.66M
Other Short-Term Assets $5.500M
YoY Change -26.02%
Inventory $13.38M
Prepaid Expenses
Receivables $13.31M
Other Receivables $0.00
Total Short-Term Assets $92.92M
YoY Change -33.83%
LONG-TERM ASSETS
Property, Plant & Equipment $1.235M
YoY Change -82.78%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $187.0K
YoY Change -33.69%
Total Long-Term Assets $5.767M
YoY Change -22.64%
TOTAL ASSETS
Total Short-Term Assets $92.92M
Total Long-Term Assets $5.767M
Total Assets $98.69M
YoY Change -33.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.156M
YoY Change -10.52%
Accrued Expenses $17.08M
YoY Change -30.79%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $11.40M
YoY Change
Total Short-Term Liabilities $37.50M
YoY Change 10.59%
LONG-TERM LIABILITIES
Long-Term Debt $32.91M
YoY Change -35.4%
Other Long-Term Liabilities $41.00K
YoY Change -99.25%
Total Long-Term Liabilities $32.95M
YoY Change -41.62%
TOTAL LIABILITIES
Total Short-Term Liabilities $37.50M
Total Long-Term Liabilities $32.95M
Total Liabilities $74.10M
YoY Change -17.98%
SHAREHOLDERS EQUITY
Retained Earnings -$795.7M
YoY Change 5.97%
Common Stock $820.3M
YoY Change 1.46%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $24.59M
YoY Change
Total Liabilities & Shareholders Equity $98.69M
YoY Change -33.27%

Cashflow Statement

Concept 2024 Q3 2024 Q2

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001560241
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
52758191 shares
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15074000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
32218000 usd
CY2024Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
63000 usd
CY2023Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
63000 usd
CY2024Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
45656000 usd
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
49938000 usd
CY2024Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
13309000 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
12687000 usd
CY2024Q2 us-gaap Inventory Net
InventoryNet
13383000 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
12442000 usd
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5437000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7600000 usd
CY2024Q2 us-gaap Assets Current
AssetsCurrent
92922000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
114948000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1476000 usd
CY2024Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
187000 usd
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
187000 usd
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4345000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4908000 usd
CY2024Q2 us-gaap Other Assets
OtherAssets
0 usd
CY2023Q4 us-gaap Other Assets
OtherAssets
21000 usd
CY2024Q2 us-gaap Assets
Assets
98689000 usd
CY2023Q4 us-gaap Assets
Assets
121540000 usd
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
5156000 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3992000 usd
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
17081000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
21893000 usd
CY2024Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
949000 usd
CY2023Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
620000 usd
dei Document Type
DocumentType
10-Q
dei Security12b Title
Security12bTitle
Common Stock $.0001 par value
dei Trading Symbol
TradingSymbol
GTHX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1235000 usd
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.10
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.37
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51667099 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52323436 shares
dei Entity File Number
EntityFileNumber
001-38096
gthx Other Nonoperating Interest Expense
OtherNonoperatingInterestExpense
4704000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3105000 usd
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5469000 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
10018000 usd
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
dei Amendment Flag
AmendmentFlag
false
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Entity Registrant Name
EntityRegistrantName
G1 THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-3648180
dei Entity Address Address Line1
EntityAddressAddressLine1
700 Park Offices Drive
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 200
dei Entity Address City Or Town
EntityAddressCityOrTown
Research Triangle Park
dei Entity Address State Or Province
EntityAddressStateOrProvince
NC
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
27709
dei City Area Code
CityAreaCode
919
dei Local Phone Number
LocalPhoneNumber
213-9835
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
29716000 usd
CY2024Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
32906000 usd
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
51557000 usd
CY2024Q2 us-gaap Deferred Revenue
DeferredRevenue
0 usd
CY2024Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
41000 usd
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
41000 usd
CY2024Q2 us-gaap Liabilities
Liabilities
74097000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
86154000 usd
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
52724545 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
51952741 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
52697879 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
51926075 shares
CY2024Q2 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
5000 usd
CY2023Q4 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
5000 usd
CY2023Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
26666 shares
CY2024Q2 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
26666 shares
CY2024Q2 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
8000 usd
CY2023Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
8000 usd
CY2024Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
820268000 usd
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
815374000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-779985000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
24592000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
35386000 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
98689000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
121540000 usd
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Transition Report
DocumentTransitionReport
false
CY2024Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
11412000 usd
CY2023Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
0 usd
CY2024Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2906000 usd
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
3211000 usd
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
37504000 usd
CY2023Q4 us-gaap Deferred Revenue
DeferredRevenue
500000 usd
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3646000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4340000 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-795673000 usd
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
16546000 usd
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
42392000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
31022000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
55338000 usd
CY2024Q2 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
733000 usd
CY2023Q2 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
1404000 usd
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
1812000 usd
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
2863000 usd
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5738000 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12040000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13056000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
27520000 usd
CY2024Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
13610000 usd
CY2023Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
17432000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
28737000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
39185000 usd
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
20081000 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
30876000 usd
us-gaap Operating Expenses
OperatingExpenses
43605000 usd
us-gaap Operating Expenses
OperatingExpenses
69568000 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3535000 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
11516000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-12583000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-14230000 usd
CY2024Q2 gthx Other Nonoperating Interest Income
OtherNonoperatingInterestIncome
225000 usd
CY2023Q2 gthx Other Nonoperating Interest Income
OtherNonoperatingInterestIncome
643000 usd
gthx Other Nonoperating Interest Income
OtherNonoperatingInterestIncome
506000 usd
gthx Other Nonoperating Interest Income
OtherNonoperatingInterestIncome
1359000 usd
CY2024Q2 gthx Other Nonoperating Interest Expense
OtherNonoperatingInterestExpense
2726000 usd
CY2023Q2 gthx Other Nonoperating Interest Expense
OtherNonoperatingInterestExpense
2710000 usd
gthx Other Nonoperating Interest Expense
OtherNonoperatingInterestExpense
5799000 usd
CY2024Q2 gthx Other Income Expense
OtherIncomeExpense
567000 usd
CY2023Q2 gthx Other Income Expense
OtherIncomeExpense
569000 usd
gthx Other Income Expense
OtherIncomeExpense
1093000 usd
gthx Other Income Expense
OtherIncomeExpense
1093000 usd
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1934000 usd
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1498000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3347000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-15688000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-17577000 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1308000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1308000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-5469000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
8710000 usd
us-gaap Net Income Loss
NetIncomeLoss
-15688000 usd
us-gaap Net Income Loss
NetIncomeLoss
-18885000 usd
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.17
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.30
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.10
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.14
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.30
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.37
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52475190 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51657456 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
52475190 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
61040507 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
52323436 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51657456 shares
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
35386000 usd
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
0 usd
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
26000 usd
CY2024Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2546000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-10219000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
27739000 usd
CY2024Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
0 usd
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
232000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2090000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-5469000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
24592000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
68747000 usd
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
-1000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3836000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-27595000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
44988000 usd
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
40000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
0 usd
CY2023Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3810000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
8710000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
57548000 usd
us-gaap Profit Loss
ProfitLoss
-15688000 usd
us-gaap Profit Loss
ProfitLoss
-18885000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
4636000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
7646000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1235000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1097000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
241000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
262000 usd
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
128000 usd
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
354000 usd
gthx Accretion Of Debt Issuance Costs
AccretionOfDebtIssuanceCosts
1391000 usd
gthx Accretion Of Debt Issuance Costs
AccretionOfDebtIssuanceCosts
486000 usd
gthx Non Cash Interest Expense
NonCashInterestExpense
493000 usd
gthx Non Cash Interest Expense
NonCashInterestExpense
630000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
622000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2077000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
941000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-579000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2763000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-657000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1137000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2020000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-6304000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1139000 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-171000 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-364000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14172000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14968000 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
53683000 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
65244000 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
59200000 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
68500000 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
1000 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
5518000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
3256000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
258000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1000 usd
us-gaap Repayments Of Debt
RepaymentsOfDebt
8195000 usd
us-gaap Repayments Of Debt
RepaymentsOfDebt
25000000 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
553000 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
1688000 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
281000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-8490000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-26968000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-17144000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-38680000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
32468000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
94907000 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
15324000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
56227000 usd
us-gaap Interest Paid Net
InterestPaidNet
3335000 usd
us-gaap Interest Paid Net
InterestPaidNet
5179000 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-795700000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-780000000 usd
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div>The preparation of condensed financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed financial statements and the accompanying notes. On an ongoing basis, the Company’s management evaluates its estimates which include, but are not limited to, estimates related to accrued expenses, accrued external clinical costs, net product sales, and stock-based compensation expense. Actual results could differ from those estimates.
CY2024Q2 us-gaap Restricted Cash
RestrictedCash
250000 usd
CY2024Q2 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
300000 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents. Deposits with financial institutions are insured, up to certain limits, by the Federal Deposit Insurance Corporation (“FDIC”). The Company’s cash deposits often exceed the FDIC insurance limit; however, all deposits are maintained with high credit quality institutions and the Company has not experienced any losses in such accounts. The financial condition of financial institutions is periodically reassessed, and the Company believes the risk of any loss on cash due to credit risk is minimal.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company's product sales are made to three distributor organizations, none of which individually contributed more than fifty percent of product sales during the reporting periods ended June 30, 2024 or December 31, 2023. The sales to these three organizations accounted for 97% and 88% of gross accounts receivable, as of June 30, 2024 and December 31, 2023, respectively. Based on an analysis of historical payment patterns for such customers, the Company believes the risk of loss is minimal, as the Company has not experienced any material losses from uncollectible accounts.</span></div>
CY2024Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 usd
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 usd
CY2023Q4 us-gaap Accrued Income Taxes
AccruedIncomeTaxes
0 usd
CY2024Q2 us-gaap Accrued Income Taxes
AccruedIncomeTaxes
0 usd
CY2024Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
45656000 usd
CY2024Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
60747000 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
49938000 usd
CY2023Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
82048000 usd
CY2024Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
2442000 usd
CY2023Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
2422000 usd
CY2024Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
9185000 usd
CY2023Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
9593000 usd
CY2024Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1756000 usd
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
427000 usd
CY2024Q2 us-gaap Inventory Net
InventoryNet
13383000 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
12442000 usd
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2577000 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2339000 usd
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1235000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1476000 usd
CY2024Q2 us-gaap Depreciation
Depreciation
121000 usd
us-gaap Depreciation
Depreciation
241000 usd
CY2023Q2 us-gaap Depreciation
Depreciation
130000 usd
us-gaap Depreciation
Depreciation
262000 usd
CY2024Q2 gthx Accrued External Research
AccruedExternalResearch
25000 usd
CY2023Q4 gthx Accrued External Research
AccruedExternalResearch
109000 usd
CY2024Q2 gthx Accrued Professional Fees And Other Current
AccruedProfessionalFeesAndOtherCurrent
6752000 usd
CY2023Q4 gthx Accrued Professional Fees And Other Current
AccruedProfessionalFeesAndOtherCurrent
5854000 usd
CY2024Q2 gthx Accrued External Clinical Study Costs
AccruedExternalClinicalStudyCosts
8332000 usd
CY2023Q4 gthx Accrued External Clinical Study Costs
AccruedExternalClinicalStudyCosts
10944000 usd
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1972000 usd
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4986000 usd
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
17081000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
21893000 usd
CY2024Q2 gthx Loan Payable Principal
LoanPayablePrincipal
41800000 usd
CY2024Q2 gthx Loan Payable Principal
LoanPayablePrincipal
41805000 usd
CY2023Q4 gthx Loan Payable Principal
LoanPayablePrincipal
50000000 usd
CY2024Q2 gthx Loan Payable End Of Term Charges
LoanPayableEndOfTermCharges
4907000 usd
CY2023Q4 gthx Loan Payable End Of Term Charges
LoanPayableEndOfTermCharges
5460000 usd
CY2024Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
46712000 usd
CY2023Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
55460000 usd
CY2024Q2 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
2394000 usd
CY2023Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
3903000 usd
CY2024Q2 us-gaap Long Term Debt
LongTermDebt
44318000 usd
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
51557000 usd
CY2024Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
11400000 usd
CY2024Q2 gthx Long Term Debt Current Maturities Gross
LongTermDebtCurrentMaturitiesGross
13000000.0 usd
CY2024Q2 us-gaap Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
200000 usd
CY2024Q2 us-gaap Debt Instrument Interest Rate Effective Percentage
DebtInstrumentInterestRateEffectivePercentage
0.218
CY2023Q2 us-gaap Debt Instrument Interest Rate Effective Percentage
DebtInstrumentInterestRateEffectivePercentage
0.182
CY2024Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
4700000 usd
CY2024Q2 gthx Debt Instrument End Of Term Fee Amount
DebtInstrumentEndOfTermFeeAmount
1400000 usd
us-gaap Interest Expense Debt
InterestExpenseDebt
5800000 usd
CY2023Q2 gthx Debt Instrument End Of Term Fee Amount
DebtInstrumentEndOfTermFeeAmount
500000 usd
CY2024Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
1517000 usd
CY2024Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
21685000 usd
CY2024Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
23510000 usd
CY2024Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
46712000 usd
CY2024Q2 gthx Common Stock Number Of Votes Per Share
CommonStockNumberOfVotesPerShare
1 vote
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
11365634 shares
CY2023Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
11040885 shares
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2090000 usd
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3810000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4636000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7646000 usd
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6774186 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
13.60
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y4M24D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
944000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1316180 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.98
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
906201 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
12.26
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
179835 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.44
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7004330 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.09
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y6M
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
379000 usd
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4813088 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
15.80
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y6M
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
859000 usd
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
6774186 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
13.60
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y4M24D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
944000 usd
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4864314 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
15.06
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y6M
CY2024Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
373000 usd
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
7004330 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
12.09
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y6M
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
379000 usd
CY2024Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9346063 shares
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9373408 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9693031 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9309917 shares
CY2024Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2023Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.131
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.074
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
gthx-20240630_cal.xml Edgar Link unprocessable
0001628280-24-036149-index-headers.html Edgar Link pending
0001628280-24-036149-index.html Edgar Link pending
0001628280-24-036149.txt Edgar Link pending
0001628280-24-036149-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
gthx-20240630.htm Edgar Link pending
gthx-20240630.xsd Edgar Link pending
gthx-20240630xex105.htm Edgar Link pending
gthx-20240630xex106.htm Edgar Link pending
gthx-20240630xex107.htm Edgar Link pending
gthx-20240630xex311.htm Edgar Link pending
gthx-20240630xex312.htm Edgar Link pending
gthx-20240630xex321.htm Edgar Link pending
gthx-20240630xex322.htm Edgar Link pending
gthx-20240630_g1.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
gthx-20240630_def.xml Edgar Link unprocessable
gthx-20240630_lab.xml Edgar Link unprocessable
gthx-20240630_pre.xml Edgar Link unprocessable
gthx-20240630_htm.xml Edgar Link completed
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending